Galderma Shares Gain After Sales Increase, Confidence on Outlook

By Sarah Sloat

Shares in Galderma gained after the Swiss skin-care company reported a jump in sales and said it was confident about navigating a volatile environment this year.

Galderma shares traded 4.8% higher at 157.85 Swiss francs in early European trading.

The company on Thursday reported first-quarter sales of $1.47 billion, a rise of 25.5% in constant currencies, and 30.5% on a reported basis. Growth was supported by sales of the Nemluvio prescription skin treatment, Galderma said.

The company, which went public in 2024, confirmed its outlook for the full year.

Galderma said its exposure to U.S. tariffs should remain manageable this year. In addition to the 15% U.S. tariff already assumed on the import values of its Sculptra and Restylane products, Galderma said its guidance takes into account the expected effects of the recent U.S. proclamation on imports of pharmaceuticals and pharmaceutical ingredients.

Vontobel analyst Stefan Schneider called the results impressive and said he expected Nemluvio growth to accelerate again in the second half. The prospect of U.S. approval for neuromodulator Relfydess should support growth in the second half and beyond, he said.

Write to Sarah Sloat at [e-mail]

(END) Dow Jones Newswires

04-23-26 0419ET